28/01/2026
New research, ancient roots. 🌿🔬
A comprehensive new review has just been published examining how Traditional Chinese Medicine is being explored for rare and intractable diseases, and the findings are genuinely encouraging.
Published in Intractable & Rare Diseases Research by teams from Qinghai University and the Japan Institute for Health Security, the paper systematically reviews clinical and experimental research on TCM treatments for conditions like ALS, systemic lupus erythematosus, aplastic anaemia, and Wilson's disease.
What makes this research particularly interesting is its focus on the multi-target mechanisms of Chinese herbal formulas. Unlike single-target conventional drugs, TCM compounds work through multiple pathways simultaneously: immune regulation, antioxidative stress, and neuroprotection.
The review highlights clinical evidence for specific formulas. For instance, a meta-analysis showed Huangqi Injection combined with androgens achieved response rates approximately 50% higher than androgen therapy alone in aplastic anaemia patients. Randomised controlled trials on Huoling Shengji Decoction showed positive effects for ALS patients.
The researchers also explore how traditional TCM concepts like "syndrome differentiation" and personalised treatment align with modern precision medicine approaches.
There's still work to be done. The authors call for more high-quality multicentre trials and enhanced mechanistic studies. But this kind of rigorous academic research helps bridge the gap between traditional knowledge and modern evidence-based practice.
We're always encouraged to see TCM being explored through modern scientific methods. Ancient roots, contemporary validation.
Read the full paper at jstage.jst.go.jp
www.phoenixmedical.com
